Baxalta Inc (BXLT) : Reilly Financial Advisors reduced its stake in Baxalta Inc by 3.52% during the most recent quarter end. The investment management company now holds a total of 246,928 shares of Baxalta Inc which is valued at $10,217,881 after selling 9,002 shares in Baxalta Inc , the firm said in a disclosure report filed with the SEC on Apr 20, 2016.Baxalta Inc makes up approximately 2.23% of Reilly Financial Advisors’s portfolio.
Baxalta Inc opened for trading at $41.18 and hit $41.41 on the upside on Friday, eventually ending the session at $41.38, with a gain of 0.73% or 0.3 points. The heightened volatility saw the trading volume jump to 39,07,482 shares. Company has a market cap of $28,190 M.
Other Hedge Funds, Including , Marathon Asset Management Llp sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 1,082,449 shares of BXLT which is valued $44,791,740. Round Table Services sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 8,205 shares of BXLT which is valued $332,385.Oakbrook Investments boosted its stake in BXLT in the latest quarter, The investment management firm added 1,400 additional shares and now holds a total of 32,740 shares of Baxalta Inc which is valued at $1,326,297. Baxalta Inc makes up approx 0.08% of Oakbrook Investments’s portfolio. Daiwa Sb Investments Ltd. added BXLT to its portfolio by purchasing 4,240 company shares during the most recent quarter which is valued at $171,762. Baxalta Inc makes up approx 0.04% of Daiwa Sb Investments Ltd.’s portfolio.
On the company’s financial health, Baxalta Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.